These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 18714001)

  • 1. Tumor-induced CD11b+Gr-1+ myeloid cells suppress T cell sensitization in tumor-draining lymph nodes.
    Watanabe S; Deguchi K; Zheng R; Tamai H; Wang LX; Cohen PA; Shu S
    J Immunol; 2008 Sep; 181(5):3291-300. PubMed ID: 18714001
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of interleukin-1 alpha on the in vitro activation of tumor-draining lymph node cells for adoptive immunotherapy.
    Hammel JM; Tuck MK; Hain JM; Chang AE; Sondak VK
    J Immunother Emphasis Tumor Immunol; 1994 Jul; 16(1):1-12. PubMed ID: 8081555
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adoptive immunotherapy of advanced tumors with CD62 L-selectin(low) tumor-sensitized T lymphocytes following ex vivo hyperexpansion.
    Wang LX; Chen BG; Plautz GE
    J Immunol; 2002 Sep; 169(6):3314-20. PubMed ID: 12218152
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Myeloid-derived suppressor cell activation by combined LPS and IFN-gamma treatment impairs DC development.
    Greifenberg V; Ribechini E; Rössner S; Lutz MB
    Eur J Immunol; 2009 Oct; 39(10):2865-76. PubMed ID: 19637228
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Different cytokine profiles released by CD4+ and CD8+ tumor-draining lymph node cells involved in mediating tumor regression.
    Aruga A; Aruga E; Cameron MJ; Chang AE
    J Leukoc Biol; 1997 Apr; 61(4):507-16. PubMed ID: 9103238
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor-induced L-selectinhigh suppressor T cells mediate potent effector T cell blockade and cause failure of otherwise curative adoptive immunotherapy.
    Peng L; Kjaergäard J; Plautz GE; Awad M; Drazba JA; Shu S; Cohen PA
    J Immunol; 2002 Nov; 169(9):4811-21. PubMed ID: 12391191
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Augmentation versus inhibition: effects of conjunctional OX-40 receptor monoclonal antibody and IL-2 treatment on adoptive immunotherapy of advanced tumor.
    Kjaergaard J; Peng L; Cohen PA; Drazba JA; Weinberg AD; Shu S
    J Immunol; 2001 Dec; 167(11):6669-77. PubMed ID: 11714839
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cancer-expanded myeloid-derived suppressor cells induce anergy of NK cells through membrane-bound TGF-beta 1.
    Li H; Han Y; Guo Q; Zhang M; Cao X
    J Immunol; 2009 Jan; 182(1):240-9. PubMed ID: 19109155
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adoptive immunotherapy with tumor-specific T lymphocytes generated from cytokine gene-modified tumor-primed lymph node cells.
    Ohno K; Yoshizawa H; Tsukada H; Takeda T; Yamaguchi Y; Ichikawa K; Maruyama Y; Suzuki Y; Suzuki E; Arakawa M
    J Immunol; 1996 May; 156(10):3875-81. PubMed ID: 8621926
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Helper-independent, L-selectinlow CD8+ T cells with broad anti-tumor efficacy are naturally sensitized during tumor progression.
    Peng L; Kjaergaard J; Plautz GE; Weng DE; Shu S; Cohen PA
    J Immunol; 2000 Nov; 165(10):5738-49. PubMed ID: 11067932
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cross-presentation of tumor antigens to effector T cells is sufficient to mediate effective immunotherapy of established intracranial tumors.
    Plautz GE; Mukai S; Cohen PA; Shu S
    J Immunol; 2000 Oct; 165(7):3656-62. PubMed ID: 11034369
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor-induced suppression of antitumor reactivity and depression of TCRzeta expression in tumor-draining lymph node lymphocytes: possible relationship to the Th2 pathway.
    Fu EJ; Arca MJ; Hain JM; Krinock R; Rado J; Cameron MJ; Chang AE; Sondak VK
    J Immunother; 1997 Mar; 20(2):111-22. PubMed ID: 9087383
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hierarchy of immunosuppressive strength among myeloid-derived suppressor cell subsets is determined by GM-CSF.
    Dolcetti L; Peranzoni E; Ugel S; Marigo I; Fernandez Gomez A; Mesa C; Geilich M; Winkels G; Traggiai E; Casati A; Grassi F; Bronte V
    Eur J Immunol; 2010 Jan; 40(1):22-35. PubMed ID: 19941314
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vivo suppressive function of myeloid-derived suppressor cells is limited to the inflammatory site.
    Haverkamp JM; Crist SA; Elzey BD; Cimen C; Ratliff TL
    Eur J Immunol; 2011 Mar; 41(3):749-59. PubMed ID: 21287554
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Depletion of CD4+ CD25+ regulatory cells augments the generation of specific immune T cells in tumor-draining lymph nodes.
    Tanaka H; Tanaka J; Kjaergaard J; Shu S
    J Immunother; 2002; 25(3):207-17. PubMed ID: 12000862
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Successful adoptive immunotherapy of murine poorly immunogenic tumor with specific effector cells generated from gene-modified tumor-primed lymph node cells.
    Tanaka H; Yoshizawa H; Yamaguchi Y; Ito K; Kagamu H; Suzuki E; Gejyo F; Hamada H; Arakawa M
    J Immunol; 1999 Mar; 162(6):3574-82. PubMed ID: 10092816
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cyclophosphamide-induced myeloid-derived suppressor cell population is immunosuppressive but not identical to myeloid-derived suppressor cells induced by growing TC-1 tumors.
    Mikyšková R; Indrová M; Polláková V; Bieblová J; Símová J; Reiniš M
    J Immunother; 2012 Jun; 35(5):374-84. PubMed ID: 22576342
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Simultaneous targeting of CD3 on T cells and CD40 on B or dendritic cells augments the antitumor reactivity of tumor-primed lymph node cells.
    Li Q; Grover AC; Donald EJ; Carr A; Yu J; Whitfield J; Nelson M; Takeshita N; Chang AE
    J Immunol; 2005 Aug; 175(3):1424-32. PubMed ID: 16034078
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Functional characterization of myeloid-derived suppressor cell subpopulations during the development of experimental arthritis.
    Wang W; Jiao Z; Duan T; Liu M; Zhu B; Zhang Y; Xu Q; Wang R; Xiong Y; Xu H; Lu L
    Eur J Immunol; 2015 Feb; 45(2):464-73. PubMed ID: 25352399
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Myeloid-derived suppressor cells attenuate TH1 development through IL-6 production to promote tumor progression.
    Tsukamoto H; Nishikata R; Senju S; Nishimura Y
    Cancer Immunol Res; 2013 Jul; 1(1):64-76. PubMed ID: 24777249
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.